Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.

MLA

Nebot, Noelia, et al. “Evaluation of the Effect of Dabrafenib and Metabolites on QTc Interval in Patients with BRAF V600-Mutant Tumours.” British Journal of Clinical Pharmacology, vol. 84, no. 4, Apr. 2018, pp. 764–75. EBSCOhost, https://doi.org/10.1111/bcp.13488.

APA

Nebot, N., Arkenau, H.-T., Infante, J. R., Chandler, J. C., Weickhardt, A., Lickliter, J. D., Sarantopoulos, J., Gordon, M. S., Mak, G., St-Pierre, A., Tang, L., Mookerjee, B., Carson, S. W., Hayes, S., & Grossmann, K. F. (2018). Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours. British Journal of Clinical Pharmacology, 84(4), 764–775. https://doi.org/10.1111/bcp.13488

Chicago

Nebot, Noelia, Hendrik-Tobias Arkenau, Jeffrey R Infante, Jason C Chandler, Andrew Weickhardt, Jason D Lickliter, John Sarantopoulos, et al. 2018. “Evaluation of the Effect of Dabrafenib and Metabolites on QTc Interval in Patients with BRAF V600-Mutant Tumours.” British Journal of Clinical Pharmacology 84 (4): 764–75. doi:10.1111/bcp.13488.